These early results provide a mechanism by which AQP1 can regulate PASMC fate and suggest that further investigation could provide additional clues as to whether AQP1‐mediated apoptosis resistance contributes to PAH development or progression and whether AQP1 might be a suitable target for therapy. This evidence concerns the gene AQP1 and pulmonary arterial hypertension.